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Background
Hyperzincaemia and hypercalprotectinaemia, a rare con-
dition within the spectrum of autoinflammatory dis-
eases, is associated with recurrent infections,
hepatosplenomegaly, arthritis, anemia, cutaneous inflam-
m a t i o n ,a n df a i l u r et ot h r i v e .S of a r ,n og e n e t i cc a u s e
has been identified in these patients. While the clinical
appearance is heterogeneous, all affected individuals pre-
sent with extremely elevated S100A8/S100A9 (calprotec-
tin) serum concentrations (0.9-12.0 g/l (normal range <
0.001 g/l)).
Aim
The clinical phenotype of 8 patients was characterized.
Screening of candidate genes PSTPIP1 and MEFV was
performed in 7 hyperzincaemia and hypercalprotectinae-
mia patients to identify disease-causing mutations.
Methods
Serum concentrations of S100A8/S100A9 were analyzed
by an ELISA assay in 8 patients with hyperzincaemia
and hypercalprotectinaemia and compared to PAPA
patients with and without treatment. Candidate exons
were amplified by PCR and sequenced on an ABI 3130
Genetic Analyzer.
Results
Seven of the eight patients were heterozygous carriers of
a glutamic acid 250 (GAG)®lysine (AAG)/p.Glu250Lys/
E 2 5 0 Ks u b s t i t u t i o ni ne x o n1 1o ft h ePSTPIP1 gene.
S100A8/S100A9 concentrations were extremely elevated
in these patients (0.9-12 g/l) compared to seven patients
presenting with classical PAPA symptoms (0.02-0.35 g/
l), whose levels again were significantly higher compared
to normal controls.
Conclusion
The PSTPIP1 E250K mutation causes an autoinflamma-
tory disorder known as hyperzincaemia and hypercal-
protectinaemia. The disease causes a heterogeneous
spectrum of symptoms that only partially overlaps with
the presentation of the classical PAPA syndrome. Ele-
vated S100A8/A9 levels are a common hallmark and
biomarker of disorders caused by mutations in the
PSTPIP1 gene.
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